Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
HOME > REGULATORY
REGULATORY
- CEFP Calls for Planned Healthcare Investments over Years
March 24, 2022
- Tentative List of Priority Infectious Diseases Expected by End of March
March 24, 2022
- PMDA to Publish Examples of Shortfalls Found in GMP Inspections
March 24, 2022
- Enhertu Braced for Price Cuts as Chuikyo OKs CEA Results; Evrysdi Not Subject to Scheme
March 24, 2022
- Alexion’s Bleeding Antidote to Be Approved as Early as This Month
March 24, 2022
- Pfizer COVID Booster OK’ed for Ages 12-17, Comirnaty Label Revised
March 24, 2022
- Ensure Appropriate Care System for Post-COVID Vaccination Symptoms: MHLW Panels
March 23, 2022
- PMDA to Launch “GMP Roundtable” with Academia, Industry
March 23, 2022
- Kyowa Pharma to Face Biz Suspension Order over Manufacturing Flaws
March 23, 2022
- AMED’s SCARDA Boots Up as Command Tower for Vaccine Development
March 23, 2022
- MHLW to Order Label Revision for Somatropin, IFNβ-1a/1b Preparations
March 23, 2022
- Safety Panel OKs FY2022 Survey on US, EU Quality Control Systems, Questions Lagevrio Measures
March 22, 2022
- Conduct Yearly Surprise GMP Inspections for High-Risk Sites: MHLW
March 22, 2022
- Veklury Expands Label for Mild COVID-19
March 22, 2022
- MHLW Panel to Discuss Pfizer COVID Booster for Ages 12-17
March 18, 2022
- PM Vows Effective Supply Chain Surveys as Economic Security Bill Enters Diet
March 18, 2022
- MHLW to Ponder Integration of Drug Supply Info with Industry Input: Minister
March 17, 2022
- LDP Project Team to Discuss Fourth COVID Shot
March 17, 2022
- Japan to Secure Extra 3 Million Doses of COVID Drugs, 145 Million Vaccine Shots Too: PM
March 17, 2022
- Economic Security Bill to Enter Diet Deliberations on March 17
March 17, 2022
ページ
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan is pressing ahead with broader drug price cuts under its cost-effectiveness assessment (CEA) system, despite lingering questions over the…
Members of a key reimbursement policy panel on October 28 raised no objections to expanding drug makers’ access to deliberations…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…